Yuhan Corporation (KRX:000105)
South Korea · Delayed Price · Currency is KRW 105,000
+1,000 (0.96%)
At close: Oct 31, 2025
Yuhan Revenue
Yuhan had revenue of 578.99B KRW in the quarter ending June 30, 2025, with 9.59% growth. This brings the company's revenue in the last twelve months to 2.17T, up 14.38% year-over-year. In the year 2024, Yuhan had annual revenue of 2.07T with 11.23% growth.
Revenue (ttm)
2.17T
Revenue Growth
+14.38%
P/S Ratio
4.02
Revenue / Employee
1.05B
Employees
2,066
Market Cap
8.71T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.07T | 208.81B | 11.23% |
| Dec 31, 2023 | 1.86T | 83.14B | 4.68% |
| Dec 31, 2022 | 1.78T | 88.04B | 5.22% |
| Dec 31, 2021 | 1.69T | 67.95B | 4.19% |
| Dec 31, 2020 | 1.62T | 139.51B | 9.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |